UNSPSC 51272102: Amylocaine

This classification denotes an anesthetic agent with the molecular formula C14H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRW683O56T, chemically known as 2-butanol, 1-(dimethylamino)-2-methyl-, benzoate (ester) but generally known as amylocaine, which bears US NIH Compound Identifier 10767. Amylocaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Amylocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12893MIG.

As of Q4 2014, AMYLOCAINE remains the US FDA Preferred Term for this commodity. Amylocaine bears US NLM identifiers UMLS ID C0081580 and NCI Concept Code C72170. SMILES: O(C(CN(C)C)(CC)C)C(=O)C1CCCCC1.

UNSPSC 51272102 Amylocaine, a Commodity code, encompasses local anesthetic pharmaceutical products that state and local health agencies, public health departments, and emergency services procure for community health initiatives and clinical programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for opioid response, generic multi-source pharmaceuticals through cooperative purchasing arrangements, and prescription fulfillment programs managed directly with manufacturers—work that extends beyond amylocaine's narrow scope to cover a broader class of pharmaceutical procurement. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). These jurisdictions typically structure pharmaceutical procurements as competitive bids with fixed-fee or unit-pricing models, quarterly or periodic deliveries, and compliance requirements around cGMP certification, Drug Supply Chain Security Act adherence, E-Verify, and insurance coverage. Vendors must work through authorized drug wholesalers or submit direct proposals with detailed product specifications including National Drug Codes and expiration-date certifications.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefit management, a preliminary information-gathering phase before formal RFP release. MMCAP, administered by Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline, establishing multi-year contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson; the RFP weights price competitiveness at 75 percent and requires vendors to maintain commercial general liability of $5 million, network security liability of $2 million, and professional liability of $2 million. Cooperative purchasing vehicles dominate the procurement landscape, allowing participating jurisdictions to leverage collective volume for better terms.